Literature DB >> 804868

Influence of tubercle aggregate size on severity of adjuvant arthritis in the rat.

S P Liyanage, H L Currey, B Vernon-Roberts.   

Abstract

Incorporation into Freund's complete adjuvant of tuberculous aggregates smaller than 90 mum in size is essential to produce adjuvant arthritis in the rat, and this correlates with a significantly greater degree of cell-mediated immunity to tuberculous antigens produced by small aggregates (smaller than 90 mum), when compared with large (larger than 90 mum) aggregates. This requirement for small aggregates to render Freund's complete adjuvant arthritogenic is not paralleled by detectable differences in antimycobacterial humoral antibody production nor by a size-dependent requirement for a conventional adjuvant effect.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 804868      PMCID: PMC1006344          DOI: 10.1136/ard.34.1.49

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

1.  Studies of arthritis and other lesions induced in rats by injection of mycobacterial adjuvant. II. Evidence that the disease is a disseminated immunologic response to exogenous antigen.

Authors:  B H WAKSMAN; C M PEARSON; J T SHARP
Journal:  J Immunol       Date:  1960-10       Impact factor: 5.422

2.  T and B cells in the blood and synovial fluid of rheumatoid patients.

Authors:  B Vernon-Roberts; H L Currey; J Perrin
Journal:  Ann Rheum Dis       Date:  1974-09       Impact factor: 19.103

3.  Inhibition of macrophage migration by a proteoglycan extracted from Kurloff cells of the guinea-pig.

Authors:  P A Revell; M F Dean; B Vernon-Roberts; H Muir; A H Marshall
Journal:  Int Arch Allergy Appl Immunol       Date:  1972

4.  Suppression of experimentally induced polyarthritis in the rat by heterologous anti-lymphocyte serum.

Authors:  H L Currey; M Ziff
Journal:  Lancet       Date:  1966-10-22       Impact factor: 79.321

5.  Immunogenicity and arthritogenicity in the rat of an antigen from Mycobacterium tuberculosis wax D.

Authors:  T Koga; C M Pearson
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

6.  Antibody to mycobacterial antigens in adjuvant arthritis (AA). I. Relationship to disease and delayed hypersensitivity.

Authors:  R J Perper; A L Oronsky; V Blancuzzi
Journal:  Arthritis Rheum       Date:  1972 May-Jun

7.  Competence of thoracic duct cells in the transfer of adjuvant disease and delayed hypersensitivity. Evidence that mycobacterial components are required for the successful transfer of the disease.

Authors:  F Quagliata; J M Phillips-Quagliata
Journal:  Cell Immunol       Date:  1972-01       Impact factor: 4.868

8.  Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens.

Authors:  G Janossy; M F Greaves
Journal:  Clin Exp Immunol       Date:  1971-10       Impact factor: 4.330

  8 in total
  11 in total

1.  Professor Barrie Vernon-Roberts, AO, MD, BSc, PhD, FRCPath, FRCPA, FAOrthA (Hon), FRS.SA.

Authors:  K D Rainsford; D R Haynes
Journal:  Inflammopharmacology       Date:  2013-07-04       Impact factor: 4.473

2.  Antibody producing capacity to the bacteriophage phi X174 in yersinia arthritis.

Authors:  R Bucknall; M Leirisalo-Repo; O Laitinen; J V Jones
Journal:  Ann Rheum Dis       Date:  1987-12       Impact factor: 19.103

3.  Effect of particle size of dried mycobacteria on adjuvant induced arthritis in the rat.

Authors:  R Best; R Christian; D A Lewis
Journal:  Agents Actions       Date:  1984-02

4.  Immunoregulatory T cells in the peripheral blood of patients with Bechterew's syndrome.

Authors:  O Vinje; J H Dobloug; O Førre; P Møller; O J Mellbye
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

5.  IgM, IgG, and IgA synthesis in vitro in persons suffering from yersinia arthritis and in patients with ankylosing spondylitis.

Authors:  R Vuento; J Eskola; R Leino; S Koskimies; M Viander
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

6.  Association of inflammation with raised serum IgA in ankylosing spondylitis.

Authors:  P Cowling; R Ebringer; A Ebringer
Journal:  Ann Rheum Dis       Date:  1980-12       Impact factor: 19.103

7.  Adjuvant arthritis in the rat. Distribution of fluorescent material after footpad injection of rhodamine-labelled tubercle bacilli.

Authors:  B Vernon-Roberts; S P Liyanage; H L Currey
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

8.  Putrescine--a potent endogenous anti-inflammatory substance in inflammatory exudates.

Authors:  J Bird; S Mohd-Hidir; D A Lewis
Journal:  Agents Actions       Date:  1983-06

9.  IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis.

Authors:  K Granfors; A Toivanen
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

10.  Depressed lymphocyte transformation by yersinia and Escherichia coli in yersinia arthritis.

Authors:  R Leino; R Vuento; S Koskimies; M Viander; A Toivanen
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.